Prevalence of antidepressants and biosimilars in elite sport

Drug Testing and Analysis

Volumn 1, Issue 6, 2009, Pages 286-291

  Machnik, M ^a   Sigmund, G ^a   Koch, A ^a   Thevis, M ^a   Schanzer W ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Antidepressant; Doping; Elite sport; Gas chromatography mass spectrometry; Selective serotonin reuptake inhibitor

Indexed keywords

GAS CHROMATOGRAPHY;

ACCREDITED LABORATORIES; ANTIDEPRESSANT; ANTIDEPRESSANT MEDICATION; BIOSIMILAR; BUPROPION; ELITE SPORT; GASCHROMATOGRAPHY-MASS SPECTROMETRY; GENERAL PUBLICS; SCREENING PROCEDURES; SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS;

SPORTS;

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYCLOBENZAPRINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; QUETIAPINE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ADULT; ARTICLE; ATHLETE; CONTROLLED STUDY; DOPING; DRUG MONITORING; ENDURANCE SPORT; FEMALE; HUMAN; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL;

EID: 77649156544     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.49     Document Type: Article

References (26)

1. F. S. Messiha, Neuro. Sci. Biobehav. Rev. 1993, 17, 385.
2. A. F. Schatzberg, J. Clin. Psychiatry 2000, 61(11), 9.
3. R. S. Duman, Neuromolecular Med. 2004, 5(1), 11.
4. J. J. Schildkraut, Am. J. Psychiatry 1965, 122, 509.
5. F. Holsboer, Neuropsychopharmacol. 2000, 23(5), 477.
6. S. M. Stahl, M. M.Grady, J. Clin. Psychiatry 2003, 64, 13.
7. P. E. Stokes, A. Holtz, Clin. Ther. 1997, 19(5), 1135.
8. S. M. Stahl, J. Clin. Psychiatry 1998, 59, 5.
9. I. Kirsch, B. J. Deacon, T. B. Huedo-Medina, A. Scoboria, T. J. Moore, B. T. Johnson, PLoSMed. 2008, 5(2), e45.
10. S. Montgomery, J. M. Ferguson, G. E. Schwartz, J. Clin. Psychopharmacol. 2003, 23(1), 45.
11. A. J. Gelenberg, R. B. Lydiard, R. L. Rudolph, L. Aguiar, J. T. Haskins, A. Salinas, JAMA 2000, 283(23), 3082.
12. J. Moncrieff, J. Nerv.Ment. Dis. 2001, 189(5), 288.
13. Stern online, http://www.stern.de/sport-motor/sportwelt/591582.html?nv= cb, accessed 6 May 2009.
14. Weltexpress online, http://www.bholstiege.de/weltexpress/dopingsucht.htm, accessed 8 July 2009.
15. B. Roelands, H. Hasegawa, P. Watson, M. F. Piacentini, L. Buyse, G. De Schutter, R. Meeusen, Eur. J. Appl. Physiol. 2009, 105(3), 493.
16. W. R. Buckett, P. C. Thomas, G. P. Luscombe, Prog. Neuropsychopharmacol. Biol. Psychiatry 1988, 12, 575.
17. M. J. Lohse, B. Müller-Oerlinghausen, in Arzneiverordnungsreport 2008, (Eds: U. Schwabe, D. Paffrath), Springer-Verlag: Berlin, 2008, pp. 773-817.
18. M. Donike, H. Geyer, A. Gotzmann, M. Kraft, F. Mandel, E. Nolteernsting, G. Opfermann, G. Sigmund, W. Schänzer, J. Zimmermann, in Official Proceedings: International Athletics Foundation World Symposium on Doping in Sport, (Eds: P. Belloni, G. Benzie, A. Ljungquist), Centro Studi & Ricerche: Firenze, 1987, pp. 53-80.
19. K. Pfleger, H. H. Maurer, A. Weber, Mass Spectral and GC Data, Part 1-4, Wiley-VCH: Weinheim, 2004.
20. S. Härtter, Pharm. Unserer Zeit 2004, 4, 296.
21. M. Machnik, G. Sigmund, W. Schänzer, in Recent Advances in Doping Analysis (13) (Eds. W. Schänzer, H. Geyer, A. Gotzmann, U. Mareck), Sportverlag Strauß: Cologne, 2005, pp. 85-93.
22. M. V. Rudorfer, W. Z. Potter, Cell.Mol. Neurobiol. 1999, 19, 373.
23. U. Breyer-Pfaff, Drug Metab. Rev. 2004, 36, 723.
24. R. Meeusen, M. F. Piacentini, S. Van Den Eynde, L. Magnus, K. De Meirleir, Int. J. Sports Medicine 2001, 22(5), 329.
25. A. W. Ravna, I. Sylte, S. G. Dahl, J. Pharmacol. Exp. Ther. 2003, 307(1), 34.
26. S. Checkley, Bailliere's Clin. Endocrinol. Metab. 1991, 5, 15.